DNA Plc’s financial information and Annual General Meeting in 2023
DNA PLC STOCK EXCHANGE RELEASE 16 November 2022, 10:00 am EET
In 2023, DNA will publish its financial statements, semi-annual report and business reviews sent as press releases as follows:
- 2 February 2023: Financial statements bulletin for 2022
- 4 May 2023: January–March 2023 business review as a press release
- 20 July 2023: Half year (January–June) 2023 financial report
- 25 October 2023: January–September 2023 business review as a press release
DNA’s electronic annual report, which contains the complete Financial Statements 2022, will be published at the latest during the week starting from 6 March 2023 (week 10/2023).
DNA's Annual General Meeting is planned to be held on 30 March 2023.To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Iceland Seafood International hf completes auction of bills28.11.2022 22:45:53 CET | Press release
Iceland Seafood International hf. has concluded an offering of 6-month bills in the new series ICESEA 23 0602. Total offers for bills in the auction amounted to ISK 1.000 million which were all accepted, at a simple rate of 9.50%. The bills are scheduled to be admitted to trading on Nasdaq Iceland in the coming weeks.
Brookfield to Present at the Goldman Sachs 2022 US Financial Services Conference28.11.2022 22:01:00 CET | Press release
BROOKFIELD, NEWS, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Brookfield Asset Management Inc. (NYSE: BAM, TSX: BAM.A) today announced that Bruce Flatt, Chief Executive Officer, is scheduled to present at the Goldman Sachs US Financial Services Conference on Wednesday, December 7, 2022, at 1:40pm ET. A live webcast will be available on the Brookfield website at https://bam.brookfield.com/news-events/events. For those unable to join the live webcast, a recording will be available on Brookfield’s website shortly after the event. About Brookfield Brookfield (NYSE: BAM, TSX: BAM.A) is a leading global alternative asset manager with over $750 billion of assets under management across real estate, infrastructure, renewable power and transition, private equity and credit. Brookfield owns and operates long-life assets and businesses, many of which form the backbone of the global economy. Utilizing its global reach, access to large-scale capital and operational expertise, Brookfield offers a range of alt
Inventiva secures a new patent expanding the IP protection of its lead product candidate lanifibranor in the US28.11.2022 22:00:00 CET | Press release
New patent granted in the United States by the USPTO covers the use of lanifibranor for the potential treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage This patent strengthens and expands the intellectual property protection of lanifibranor in the United States particularly for use for patients with cirrhotic NASH Daix (France), Long Island City (New York, United States), November 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced that the United States Patent and Trademark Office (“USPTO”) granted a patent (U.S. Patent No. 11,504,380) that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensa
EYES ON IRAN ART ACTIVATION FACES THE U.N. IN NEW YORK28.11.2022 21:04:15 CET | Press release
AN EVENT MARKED THE OPENING FEATURING HILLARY RODHAM CLINTON, GISSOU NIA,SHEIDA SOLEIMANI, SHIRIN NESHAT with SPECIAL PERFORMANCE BY JON BATISTE NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Iranian artists Sheida Soleimani, Aphrodite Désirée Navab, Z, Icy and Sot, Shirin Neshat, Mahvash Mostala, Sepideh Mehraban, and Shirin Towfiq, alongside artists Hank Willis Thomas and JR, activate New York’s FDR Four Freedoms State Park with a provocative multi-day and multi-media art installation facing the United Nations entitled Eyes on Iran, November 28, 2022 - January 1, 2023. Timed for the U.N. initiative, 16 Days of Activism Against Gender-Based Violence, the installations are focused on the power of collective sight, with eyes facing the U.N., signifying the world’s eyes on Iran. 'Eyes in the Sky' flying billboards featuring artworks by Thomas and Mostala will fly on December 3 in New York City and on November 28 and 30 in Miami. An interactive installation by artist JR will take place on
PRESS RELEASE: BIGBEN: 2022-23 HALF-YEAR RESULTS28.11.2022 18:09:56 CET | Press release
Press release Lesquin, 28 November 2022 18:00hrs 2022-23 HALF-YEAR RESULTS UP 138.5 M€ SALES (+11.6%)11.8 M€ CURRENT OPERATING RESULT (+19.6%)7.6 M€ NET RESULT (+9.6%) STRONG GROWTH AMBITION REITERATED FOR FY2023-24 CONTINUATION OF THE GAMES PUBLISHING MOMENTIUMENCOURAGING OUTLOOK FOR THE AUDIOVIDEO/TELCO BUSINESS BIGBEN INTERACTIVE (ISIN FR0000074072) today releases its audited consolidated results for 1st Half Year 2022-23 (from April 1, 2022 to September 30, 2022) as approved by its Board of directors on 28 November 2022. Consolidated in M€ - IFRS09/202209/2021 ChangeSales138.5124.2+11.6%Gross margin (1) In % of Sales EBITDA(2) In % of Sales 64.8 46.8% 28.3 20.4% 51.4 41.4% 24.6 19.8%+26.0% +15.2%Current operating income EBITA In % of Sales Non recurrent items 11.8 8.5% (1.4)9.9 8.0% (5.8) +19.6% Operating income In % of Sales 10.5 7.6%4.1 3.3%+153.6%Financial result(0.3)4.8 Earnings before tax In % of Sales 10.2 7.4%9.0 7.2%+13.5%Tax(2.6)(2.0)Net result for the period In % of Sales